We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Submit your research today!

Your valuable research in Expert Opinion on Investigational Drugs - Triple Negative Breast Cancer

About the special issue

This particular issue will tackle the field of triple negative breast cancer [TNBC]; it is designed to offer the specialist and non-specialist insights into the clinical development of novel treatment modalities whether they are monotherapies or combination therapies. It will also examine novel and established therapeutic targets which may offer opportunities to limit progression and metastasis.

This is an opportunity to gain insights on the frontiers of novel treatment approaches and get a fuller picture of the achievements and stumbling blocks in the preclinical and clinical setting.

 

Submission Information

3-5 week submission deadline: 3rd of January 2022
7-9 week submission deadline: 17th January 2022

Learn more about preparing your manuscript by visiting the Instructions for Authors page.

Commissioning Editor: Debbie Tranter

Submit here

By publishing in Expert Opinion on Investigational Drugs you will:

  1. Gain recognition from an international audience and increase your opportunities for future collaboration 
  2. Receive 50 free e-prints & promotional tips on promoting your article courtesy of our Author Services site  
  3. Immediately see the impact of your research made in the community by tracking downloads, citations, and the Altmetric Score of your article on My Authored Works  
  4. Increase the discoverability of your research with MEDLINE listings and more